Current Opinion in Ophthalmology最新文献_第8页

Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema. 加强糖尿病黄斑水肿玻璃体内抗血管内皮生长因子药物再治疗标准的持久性和演变。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-05-01 Epub Date: 2024-02-12 DOI: 10.1097/ICU.0000000000001037

Nikhil K Mandava, Ajay E Kuriyan, Allen C Ho, Jason Hsu, Carl D Regillo, Michael A Klufas

{"title":"Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema.","authors":"Nikhil K Mandava, Ajay E Kuriyan, Allen C Ho, Jason Hsu, Carl D Regillo, Michael A Klufas","doi":"10.1097/ICU.0000000000001037","DOIUrl":"10.1097/ICU.0000000000001037","url":null,"abstract":"Purpose of review: The increasing prevalence of diabetic macular edema (DME) necessitates an updated review of treatment modalities. While the shift from laser to anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed patient outcomes, benefits of these agents are not fully realized in real-world implementation relative to the setting of controlled clinical trials. This review outlines the evolution of intravitreal anti-VEGF treatment extension protocols for DME that reflect efforts to address treatment adherence challenges while optimizing visual outcomes.Recent findings: Recent studies highlight the efficacy of extended-interval dosing with anti-VEGF agents in managing DME. Trials such as RISE/RIDE, VISTA/VIVID, and LUCIDATE have established the foundation of these regimens by demonstrating sustained visual gains with continuous treatment. However, newer trials including PROTOCOL T, KESTREL/KITE, YOSEMITE/RHINE, and PHOTON have furthered this concept, revealing that less frequent dosing of various anti-VEGF agents can maintain similar visual acuity and anatomical outcomes to traditional monthly injections.Summary: The reviewed findings suggest a paradigm shift in DME treatment toward less frequent anti-VEGF injections. This has significant implications for clinical practice, potentially leading to greater adherence to treatment regimens and sustained visual function in patients, while minimizing treatment burden and healthcare costs. Further investigation into the long-term effects of extended dosing intervals is required.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"197-204"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists. 地理萎缩：当前和未来的治疗药物以及视网膜专家的实际考虑因素。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-05-01 Epub Date: 2024-02-28 DOI: 10.1097/ICU.0000000000001046

Priya Vakharia, David Eichenbaum

{"title":"Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.","authors":"Priya Vakharia, David Eichenbaum","doi":"10.1097/ICU.0000000000001046","DOIUrl":"10.1097/ICU.0000000000001046","url":null,"abstract":"Purpose of review: Geographic atrophy (GA) from age-related macular degeneration (AMD) remains a leading cause of vision loss. The purpose of this review is to summarize currently available intravitreal therapeutics, and discuss pipeline therapeutics that are currently in clinical trials.Recent findings: The FDA approval of pegcetacoplan and avacincaptad pegol, both approved in 2023, represent the first therapeutics to treat GA. These are delivered via intravitreal injections, and have been shown to slow progression of GA. Both drugs have a risk of new onset neovascular age-related macular degeneration (nAMD). Initial indications seem to be that pegcetacoplan therapy has higher risks of inflammation, vasculitis, and nonarteritic ischemic optic neuropathy (NAION) as compared to avacincaptad pegol, but more real-world data will help to clarify this further. Pipeline therapeutics that we discuss include intravitreal gene therapy, oral anticomplement therapy, and intravitreal injections of a novel glycoprotein.Summary: Both pegcetacoplan and avacincaptad pegol are FDA approved to treat GA. The decision to treat patients is still complex and nuanced, but the approval of two treatments for GA is a tremendous advance in our field. Future therapeutics may further refine our ability to treat patients more effectively and safely.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"165-169"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term outcomes of corneal crosslinking. 角膜交联术的长期效果。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-04-29 DOI: 10.1097/icu.0000000000001054

Eli K Cehelyk, Zeba A Syed

引用次数: 0

Nontraditional approaches to sedation for anterior segment surgery: a narrative review. 前节手术镇静的非传统方法：综述。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-04-25 DOI: 10.1097/icu.0000000000001051

Jeremy N Shapiro, Shahzad I Mian

引用次数: 0

Current state of endothelial cell therapy. 内皮细胞疗法的现状。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-04-12 DOI: 10.1097/icu.0000000000001050

Ellen H Koo

引用次数: 0

How much does cataract surgery contribute to intraocular pressure lowering? 白内障手术对降低眼压有多大作用?

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-11-29 DOI: 10.1097/ICU.0000000000001021

Jasdeep Sabharwal, Anupam K Garg, Pradeep Y Ramulu

{"title":"How much does cataract surgery contribute to intraocular pressure lowering?","authors":"Jasdeep Sabharwal, Anupam K Garg, Pradeep Y Ramulu","doi":"10.1097/ICU.0000000000001021","DOIUrl":"10.1097/ICU.0000000000001021","url":null,"abstract":"Purpose of review: To review the literature evaluating the effect of cataract surgery on intraocular pressure (IOP) in patients with glaucoma.Recent findings: Recent high-quality secondary analyses of large and primary trials continue to show IOP lowering following cataract surgery. Likewise, cataract surgery remains a key treatment for angle closure glaucoma. Some micro-invasive glaucoma surgeries (MIGS) have strong evidence to be performed at the time of cataract surgery. Data clarifying when these surgeries should be combined with cataract surgery is emerging. The mechanism underlying IOP lowering after cataract surgery remains unclear.Summary: Patients who are glaucoma suspects with visually significant cataracts would benefit from cataract surgery alone. Those with mild-moderate damage on 1-2 classes of medications would most likely benefit from additional MIGS. Patients with advanced disease would benefit from cataract surgery and a choice of additional surgery, which depends on disease status and patient factors. Clear lens extraction is becoming a more accepted practice as a primary procedure for patients with angle closure and high IOP or glaucoma. The role of additional MIGS in angle closure needs further study.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"147-154"},"PeriodicalIF":3.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138452993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of posterior chamber phakic intraocular lenses. 后房型晶状体人工晶状体的研究进展。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1097/ICU.0000000000001018

Dan Z Reinstein, Cheryl MacGregor, Timothy J Archer, Ruchi Gupta, Joseph G Potter

{"title":"A review of posterior chamber phakic intraocular lenses.","authors":"Dan Z Reinstein, Cheryl MacGregor, Timothy J Archer, Ruchi Gupta, Joseph G Potter","doi":"10.1097/ICU.0000000000001018","DOIUrl":"10.1097/ICU.0000000000001018","url":null,"abstract":"Purpose of review: Posterior chamber phakic intraocular lenses (pIOLs) are increasing in popularity as a viable alternative to laser refractive surgery. The purpose of this review is to evaluate the recent updates to pIOLs and to assess the advancements and safety of the procedure.Recent findings: Accurate lens sizing is the key determinant to suitable vault prediction, advancements to sizing formulae including the use of very high frequency (VHF) digital ultrasound and the application of artificial intelligence and machine learning has led to improved vault prediction and safety. The introduction of the central aquaport has been shown to reduce the formation of cataract and is now adopted in most myopic pIOLs. Recently published studies have demonstrated that pIOLs have an excellent safety profile with no increased risk of retinal detachment or endothelial cell loss. Advancements have led to the introduction of extended depth of focus pIOLs for the correction of presbyopia, further research is required to evaluate the efficacy of new lens designs.Summary: pIOL surgery is experiencing traction with improved lens design and increased lenses choices such as larger optical zone and presbyopic options. Accuracy of implantable collamer lens sizing is paramount to the safety and clinical outcomes, greater predictability is likely to encourage more posterior chamber pIOL users due to fewer sizing related complications.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"138-146"},"PeriodicalIF":3.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138500008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cataract surgery in setting of ocular surface disease. 眼表疾病的白内障手术。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-11-27 DOI: 10.1097/ICU.0000000000001024

Enrica Sarnicola, Caterina Sarnicola, Maddalena De Bernardo, Nicola Rosa, Vincenzo Sarnicola

引用次数: 0

Editorial introduction. 编辑介绍。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2024-02-08 DOI: 10.1097/ICU.0000000000001027

引用次数: 0

Recent developments of telemedicine in glaucoma. 青光眼远程医疗的最新发展。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2024-02-08 DOI: 10.1097/ICU.0000000000001019

Jason J Jo, Louis R Pasquale

{"title":"Recent developments of telemedicine in glaucoma.","authors":"Jason J Jo, Louis R Pasquale","doi":"10.1097/ICU.0000000000001019","DOIUrl":"10.1097/ICU.0000000000001019","url":null,"abstract":"Purpose of review: Telemedicine has an increasingly significant role in the fields of ophthalmology and glaucoma. This review covers recent advancements in the development and optimization of teleglaucoma techniques and applications.Recent findings: Glaucoma monitoring and diagnosis via remote tonometry, perimetry, and fundus imaging have become a possibility based on recent developments. Many applications work in combination with smart devices, virtual reality, and artificial intelligence and have been tested in patient populations against conventional \"reference-standard\" measurement tools, demonstrating promising results. Of note, there is still much progress to be made in teleglaucoma and telemedicine at large, such as accessibility to internet, broadband, and smart devices, application affordability, and reimbursement for remote services. However, continued development and optimization of these applications suggest that the implementation of remote monitoring will be a mainstay for glaucoma patient care.Summary: Especially since the beginning of the COVID-19 pandemic, remote patient care has taken on an important role in medicine and ophthalmology. Remote versions of tonometry, perimetry, and fundus imaging may allow for a more patient-centered and accessible future for glaucoma care.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"116-123"},"PeriodicalIF":3.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0